Oral delivery of siRNA lipid nanoparticles: Fate in the GI tract

Scientific Reports

Volumn 8, Issue 1, 2018, Pages

  Ball, Rebecca L ^a   Bajaj, Palak ^a   Whitehead, Kathryn A ^a  

^a CARNEGIE MELLON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LIPID; NANOPARTICLE; SMALL INTERFERING RNA;

ANIMAL; C57BL MOUSE; CACO-2 CELL LINE; CHEMISTRY; DRUG DELIVERY SYSTEM; FEMALE; GASTROINTESTINAL TRACT; GENE SILENCING; HUMAN; METABOLISM; MOUSE; ORAL DRUG ADMINISTRATION; TISSUE DISTRIBUTION;

ADMINISTRATION, ORAL; ANIMALS; CACO-2 CELLS; DRUG DELIVERY SYSTEMS; FEMALE; GASTROINTESTINAL TRACT; GENE SILENCING; HUMANS; LIPIDS; MICE; MICE, INBRED C57BL; NANOPARTICLES; RNA, SMALL INTERFERING; TISSUE DISTRIBUTION;

EID: 85041594922     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/s41598-018-20632-6     Document Type: Article

References (59)

1. Fearon, E. R. Molecular genetics of colorectal cancer. Annu. Rev. Pathol. 6, 479-507 (2011).
2. Suzuki, M. et al. Myosin light chain kinase expression induced via tumor necrosis factor receptor 2 signaling in the epithelial cells regulates the development of colitis-associated carcinogenesis. PLoS One 9 (2014).
3. Blair, S. A., Kane, S. V., Clayburgh, D. R. & Turner, J. R. Epithelial myosin light chain kinase expression and activity are upregulated in inflammatory bowel disease. Lab. Investig. 86, 191-201 (2006).
4. Clevers, H. & Nusse, R. Wnt/β-catenin signaling and disease. Cell 149, 1192-1205 (2012).
5. Han, L., Tang, C. & Yin, C. Oral delivery of shRNA and siRNA via multifunctional polymeric nanoparticles for synergistic cancer therapy. Biomaterials 35, 4589-4600 (2014).
6. Lautenschläger, C., Schmidt, C., Fischer, D. & Stallmach, A. Drug delivery strategies in the therapy of inflammatory bowel disease. Adv. Drug Deliv. Rev. 71, 58-76 (2014).
7. Jemal, A. et al. Global cancer statistics. CA Cancer J Clin 61(1), 33-64 (2011).
8. Baumgart, D. C. & Sandborn, W. J. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet 369, 1641-1657 (2007).
9. Cunliffe, R. N. & Scott, B. B. Review article: Monitoring for drug side-effects in inflammatory bowel disease. Aliment. Pharmacol. Ther. 16, 647-662 (2002).
10. Mason, M. & Siegel, C. A. Do inflammatory bowel disease therapies cause cancer? Inflamm. Bowel Dis. 19, 1306-21 (2013).
11. Stanbury, R. M. & Graham, E. M. Systemic corticosteroid therapy-side effects and their management. Br. J. Ophthalmol. 82, 704-708 (1998).
12. Liu, G., Franssen, E., Fitch, M. I. & Warner, E. Patient preferences for oral versus intravenous palliative chemotherapy. J. Clin. Oncol. 15, 110-5 (1997).
13. Liu, F. et al. Patient-centred pharmaceutical design to improve acceptability of medicines: Similarities and differences in paediatric and geriatric populations. Drugs 74, 1871-1889 (2014).
14. Forbes, D. C. & Peppas, N. A. Oral delivery of small RNA and DNA. J. Control. Release 162, 438-445 (2012).
15. Kriegel, C. & Amiji, M. Oral TNF-α gene silencing using a polymeric microsphere-based delivery system for the treatment of inflammatory bowel disease. J. Control. Release 150, 77-86 (2011).
16. He, C., Yin, L., Song, Y., Tang, C. & Yin, C. Optimization of multifunctional chitosan-siRNA nanoparticles for oral delivery applications, targeting TNF-α silencing in rats. Acta Biomater. 1-9 (2015).
17. He, C., Yin, L., Tang, C. & Yin, C. Multifunctional polymeric nanoparticles for oral delivery of TNF-α siRNA to macrophages. Biomaterials 34, 2843-2854 (2013).
18. Guo, J., O'Mahony, A. M., Cheng, W. P. & O'Driscoll, C. M. Amphiphilic polyallylamine based polymeric micelles for siRNA delivery to the gastrointestinal tract: In vitro investigations. Int. J. Pharm. 447, 150-157 (2013).
19. Ballarín-González, B. et al. Protection and Systemic Translocation of siRNA Following Oral Administration of Chitosan/siRNA Nanoparticles. Mol. Ther. Nucleic Acids 2, e76 (2013).
20. Knipe, J. M., Strong, L. E. & Peppas, N. A. Enzyme-and pH-Responsive Microencapsulated Nanogels for Oral Delivery of siRNA to Induce TNF-α Knockdown in the Intestine. Biomacromolecules 17, 788-797 (2016).
21. Aouadi, M. et al. Orally delivered siRNA targeting macrophage Map4k4 suppresses systemic inflammation. Nature 458, 1180-4 (2009).
22. Yin, L. et al. Supramolecular self-assembled nanoparticles mediate oral delivery of therapeutic TNF-α siRNA against systemic inflammation. Angew. Chemie-Int. Ed. 52, 5757-5761 (2013).
23. Wang, B. et al. Targeted Drug Delivery to Intestinal Macrophages by Bioactive Nanovesicles Released from Grapefruit. Mol. Ther. 1-13 (2013).
24. Creamer, B., Shorter, R. G. & Bamforth, J. The turnover and shedding of epithelial cells. I. The turnover in the gastro-intestinal tract. Gut 2, 110-118 (1961).
25. Xiao, B. et al. Combination Therapy for Ulcerative Colitis: Orally Targeted Nanoparticles Prevent Mucosal Damage and Relieve Inflammation. Theranostics 6, 2250-2266 (2016).
26. Kriegel, C., Attarwala, H. & Amiji, M. Multi-compartmental oral delivery systems for nucleic acid therapy in the gastrointestinal tract. Adv. Drug Deliv. Rev. 65, 891-901 (2013).
27. Arber, N., Doki, Y., Han, E., Sgambato, A. & Zhou, P. Antisense to cyclin D1 inhibits the growth and tumorigenicity of human colon cancer cells. Cancer Res. 8, 1569-1574 (1997).
28. Ball, R. L., Knapp, C. M. & Whitehead, K. A. Lipidoid Nanoparticles for siRNA Delivery to the Intestinal Epithelium: In Vitro Investigations in a Caco-2 Model. PLoS One 10, 1-12 (2015).
29. Akinc, A. et al. A combinatorial library of lipid-like materials for delivery of RNAi therapeutics. Nat. Biotechnol. 26, 561-569 (2008).
30. Whitehead, K. A. et al. Degradable lipid nanoparticles with predictable in vivo siRNA delivery activity. Nat. Commun. 5, 4277 (2014).
31. Van de Graaf, K. M. Anatomy and physiology of the gastrointestinal tract. Pediatr. Infect. Dis. 5, S11-S15 (1986).
32. Gan, K. H., Geus, W. P., Bakker, W., Lambers, C. B. H. W. & Heijerman, H. G. M. In vitro dissolution profiles of enteric-coated microsphere\microtablet pancreatin preparations at different pH values. Aliment. Pharmacol. Ther. 10, 771-775 (1996).
33. Maldonado-Valderrama, J., Wilde, P., MacIerzanka, A. & MacKie, A. The role of bile salts in digestion. Adv. Colloid Interface Sci. 165, 36-46 (2011).
34. Kalantzi, L. et al. Characterization of the human upper gastrointestinal contents under conditions simulating bioavailability/ bioequivalence studies. Pharm. Res. 23, 165-176 (2006).
35. Kararli, T. T. Comparison of the gastrointestinal anatomy, physiology, and biochemistry of humans and commonly used laboratory animals. Biopharm. Drug Dispos. 16, 351-380 (1995).
36. Sambuy, Y. et al. The Caco-2 cell line as a model of the intestinal barrier: Influence of cell and culture-related factors on Caco-2 cell functional characteristics. Cell Biol. Toxicol. 21, 1-26 (2005).
37. Press, B. & Di Grandi, D. Permeability for intestinal absorption: Caco-2 assay and related issues. Curr. Drug Metab. 9, 893-900 (2008).
38. Ensign, L. M., Cone, R. & Hanes, J. Oral drug delivery with polymeric nanoparticles: The gastrointestinal mucus barriers. Adv. Drug Deliv. Rev. 64, 557-570 (2012).
39. Boegh, M. & Nielsen, H. M. Mucus as a barrier to drug delivery-Understanding and mimicking the barrier properties. Basic Clin. Pharmacol. Toxicol. 116, 179-186 (2015).
40. Cone, R. A. Barrier properties of mucus. Adv. Drug Deliv. Rev. 61, 75-85 (2009).
41. Xu, Q., Ensign, L. M., Boylan, N. J. & Scho, A. Impact of Surface Polyethylene Glycol (PEG) Density on Biodegradable Nanoparticle Transport in Mucus ex Vivo and Distribution in Vivo. ACS Nano 9, 9217-9227 (2015).
42. Hak, S. et al. The effect of nanoparticle polyethylene glycol surface density on ligand-directed tumor targeting studied in vivo by dual modality imaging. ACS Nano 6, 5648-5658 (2012).
43. Pelaz, B. et al. Surface Functionalization of Nanoparticles with Polyethylene Glycol: Effects on Protein Adsorption and Cellular Uptake. ACS Nano 9, 6996-7008 (2015).
44. Suzuki, T. Regulation of intestinal epithelial permeability by tight junctions. Cell. Mol. Life Sci. 70, 631-659 (2013).
45. Nowarski, R. et al. Epithelial IL-18 Equilibrium Controls Barrier Function in Colitis. Cell 163, 1444-1456 (2015).
46. Ball, R. L. & Bajaj, P. Achieving long-term stability of lipid nanoparticles: examining the effect of pH, temperature, and lyophilization. Int. J. Nanomedicine 12, 305-315 (2016).
47. Aditya, N. P. et al. Development and evaluation of lipid nanocarriers for quercetin delivery: A comparative study of solid lipid nanoparticles (SLN), nanostructured lipid carriers (NLC), and lipid nanoemulsions (LNE). LWT-Food Sci. Technol. 59, 115-121 (2014).
48. Da Gama Bitencourt, J. J. et al. Miltefosine-loaded lipid nanoparticles: Improving miltefosine stability and reducing its hemolytic potential toward erythtocytes and its cytotoxic effect on macrophages. Biophys. Chem. 217, 20-31 (2016).
49. Xiat, J., Dubin, P. L. & Kokufuta, E. Dynamic and Electrophoretic Light Scattering of a Water-Soluble Complex Formed between Pepsin and Poly(ethylene glycol). Macromolecules 26, 6688-6690 (1993).
50. Spelzini, D., Peleteiro, J., Picó, G. & Farruggia, B. Polyethyleneglycol-pepsin interaction and its relationship with protein partitioning in aqueous two-phase systems. Colloids Surfaces B Biointerfaces 67, 151-156 (2008).
51. Lindahl, A., Ungell, A. L., Knutson, L. & Lennernäs, H. Characterization of fluids from the stomach and proximal jejunum in men and women. Pharmaceutical Research 14, 497-502 (1997).
52. Ensign, L. M. et al. Mucus-penetrating nanoparticles for vaginal drug delivery protect against herpes simplex virus. Sci. Transl. Med. 4, 1-16 (2012).
53. Kim, N. et al. Synthesis and characterization of mannosylated pegylated polyethylenimine as a carrier for siRNA. Int. J. Pharm. 427, 123-133 (2012).
54. Pozzi, D. et al. Effect of polyethyleneglycol (PEG) chain length on the bio-nano-interactions between PEGylated lipid nanoparticles and biological fluids: from nanostructure to uptake in cancer cells. Nanoscale 6, 2782 (2014).
55. Otsuka, H., Nagasaki, Y. & Kataoka, K. PEGylated nanoparticles for biological and pharmaceutical applications. Adv. Drug Deliv. Rev. 55, 403-419 (2003).
56. Suk, J. S., Xu, Q., Kim, N., Hanes, J. & Ensign, L. M. PEGylation as a strategy to improve nanoparticle-based drug and gene delivery. Adv. Drug Deliv. Rev. 99, 28-51 (2015).
57. Barea, M. J., Jenkins, M. J., Gaber, M. H. & Bridson, R. H. Evaluation of liposomes coated with a pH responsive polymer. Int. J. Pharm. 402, 89-94 (2010).
58. Barea, M. J., Jenkins, M. J., Lee, Y. S., Johnson, P. & Bridson, R. H. Encapsulation of liposomes within pH responsive microspheres for oral colonic drug delivery. Int. J. Biomater. 2012, 1-10 (2012).
59. Lamson, N. G., Cusimano, G., Suri, K., Zhang, A. & Whitehead, K. A. The pH of Piperazine Derivative Solutions Predicts Their Utility as Transepithelial Permeation Enhancers. Mol. Pharm. 13, 578-585 (2016).